Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)

INTRODUCTION: Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This European, phase 3, randomized, open-label, active-controlled study investigated efficacy and safety of roxadustat...

Descripción completa

Detalles Bibliográficos
Autores principales: Csiky, Botond, Schömig, Michael, Esposito, Ciro, Barratt, Jonathan, Reusch, Michael, Valluri, Udaya, Sulowicz, Wladyslaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478768/
https://www.ncbi.nlm.nih.gov/pubmed/34537926
http://dx.doi.org/10.1007/s12325-021-01904-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478768/
https://www.ncbi.nlm.nih.gov/pubmed/34537926
http://dx.doi.org/10.1007/s12325-021-01904-6

Ejemplares similares